{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:30:35Z","timestamp":1790188235247,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study aims to compare the effects of ticagrelor and clopidogrel on platelet function, cardiovascular prognosis, and bleeding in patients with unstable angina pectoris.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI) were enrolled (January 2018\u2013December 2019). In total, 212 patients were treated with ticagrelor (90\u00a0mg twice daily) and 210 patients were treated with clopidogrel (75\u00a0mg once daily). Thromboelastography and light transmission aggregometry were used to measure the platelet aggregation rate (PAR). High-sensitivity troponin T (hs-TnT), pro-brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (CRP), and heart-type fatty acid\u2013binding protein (h-FABP) were measured to assess myocardial injury after PCI. Cardiovascular prognosis and bleeding events were evaluated in hospital and 12\u00a0months after discharge.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The PAR was significantly slower with ticagrelor (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). hs-TnT, NT-proBNP, CRP, and h-FABP increased after compared with before PCI in both groups (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). hs-TnT (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and h-FABP (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) increased more significantly with clopidogrel. The in-hospital and 12-month major adverse cardiovascular event (MACE) rates were not significantly different between the two groups. The in-hospital total bleeding event rate was higher with ticagrelor (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Minor bleeding and total bleeding were more frequent at the 12-month follow-up in the ticagrelor group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Ticagrelor was more effective in suppressing the PAR than clopidogrel and reduced PCI-induced myocardial injury in patients with unstable angina pectoris. However, it increased in-hospital and 12-month bleeding events and had no benefit on in-hospital and 12-month MACEs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-022-03401-3","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:02:31Z","timestamp":1665964951000},"page":"1949-1958","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of ticagrelor and clopidogrel on platelet function and prognosis in unstable angina"],"prefix":"10.1007","volume":"78","author":[{"given":"Chun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingbo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"issue":"4","key":"3401_CR1","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/FJC.0000000000000881","volume":"76","author":"MW Mohareb","year":"2020","unstructured":"Mohareb MW, AbdElghany M, Zaki HF, El-Abhar HS (2020) Diabetes and CYP2C19 polymorphism synergistically impair the antiplatelet activity of clopidogrel compared with ticagrelor in percutaneous coronary intervention-treated acute coronary syndrome patients. J Cardiovasc Pharmacol 76(4):478\u2013488","journal-title":"J Cardiovasc Pharmacol"},{"issue":"8","key":"3401_CR2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1055\/s-0040-1713375","volume":"120","author":"Z Liu","year":"2020","unstructured":"Liu Z, Tian R, Wang Y, Chen Q, Li J, Xu L et al (2020) Platelet inhibition with ticagrelor versus clopidogrel in diabetic patients after percutaneous coronary intervention for chronic coronary syndromes. Thromb Haemost 120(8):1221\u20131229","journal-title":"Thromb Haemost"},{"issue":"5","key":"3401_CR3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/09537104.2020.1792871","volume":"32","author":"M Biswas","year":"2021","unstructured":"Biswas M, Kali MSK, Biswas TK, Ibrahim B (2021) Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel\/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. Platelets 32(5):591\u2013600","journal-title":"Platelets"},{"key":"3401_CR4","doi-asserted-by":"crossref","unstructured":"Xu F, Feng W, Zhou Z, Zhang Y, Diao X, Hu S et al (2019) Antiplatelet effects of ticagrelor versus clopidogrel after coronary artery bypass graft surgery: a single-center randomized controlled trial. J Thorac Cardiovasc Surg 158(2):430\u20137 e4","DOI":"10.1016\/j.jtcvs.2018.10.032"},{"issue":"8","key":"3401_CR5","doi-asserted-by":"publisher","first-page":"873","DOI":"10.5551\/jat.57265","volume":"28","author":"J Li","year":"2021","unstructured":"Li J, Qiu H, Yan L, Guo T, Wang Y, Li Y et al (2021) Efficacy and safety of ticagrelor and clopidogrel in patients with stable coronary artery disease undergoing percutaneous coronary intervention. J Atheroscler Thromb 28(8):873\u2013882","journal-title":"J Atheroscler Thromb"},{"key":"3401_CR6","doi-asserted-by":"crossref","unstructured":"Chang CJ, Tung YC, Liu JR, Chang SH, Kuo CT, See LC (2021) Efficacy and safety of ticagrelor vs. clopidogrel in East Asian patients with acute myocardial infarction: a nationwide cohort study. Clin Pharmacol Ther 109(2):443\u201351","DOI":"10.1002\/cpt.2011"},{"issue":"14","key":"3401_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.4244\/EIJ-D-20-00268","volume":"16","author":"M Hamilos","year":"2021","unstructured":"Hamilos M, Kanakakis J, Anastasiou I, Karvounis C, Vasilikos V, Goudevenos J et al (2021) Ticagrelor versus clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial. EuroIntervention 16(14):1163\u20131169","journal-title":"EuroIntervention"},{"key":"3401_CR8","doi-asserted-by":"crossref","unstructured":"Ueland T, Akerblom A, Ghukasyan T, Michelsen AE, Aukrust P, Becker RC et al (2018) Osteoprotegerin is associated with major bleeding but not with cardiovascular outcomes in patients with acute coronary syndromes: insights from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Heart Assoc\u00a07(2)","DOI":"10.1161\/JAHA.117.007009"},{"issue":"14","key":"3401_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017888","volume":"9","author":"BA Bergmark","year":"2020","unstructured":"Bergmark BA (2020) Real-world comparison of ticagrelor and clopidogrel: Rosetta Stone or lost in translation? J Am Heart Assoc 9(14):e017888","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"3401_CR10","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/jcpt.13172","volume":"45","author":"Y Xue","year":"2020","unstructured":"Xue Y, Hu Z, Jing Y, Wu H, Li X, Wang J et al (2020) Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine-learning decision tree approaches. J Clin Pharm Ther 45(5):1076\u20131086","journal-title":"J Clin Pharm Ther"},{"key":"3401_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2019.09.011","volume":"290","author":"Y Sun","year":"2019","unstructured":"Sun Y, Li C, Zhang L, Yu T, Ye H, Yu B et al (2019) Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients. Atherosclerosis 290:52\u201358","journal-title":"Atherosclerosis"},{"issue":"6","key":"3401_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/2048872617740832","volume":"8","author":"JJ Russo","year":"2019","unstructured":"Russo JJ, James TE, Ruel M, Dupuis JY, Singh K, Goubran D et al (2019) Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y12 receptor antagonist for acute coronary syndromes: insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery. Eur Heart J Acute Cardiovasc Care 8(6):543\u2013553","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"6","key":"3401_CR13","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.neurad.2019.01.094","volume":"46","author":"S Soize","year":"2019","unstructured":"Soize S, Foussier C, Manceau PF, Litre CF, Backchine S, Gawlitza M et al (2019) Comparison of two preventive dual antiplatelet regimens for unruptured intracranial aneurysm embolization with flow diverter\/disrupter: a matched-cohort study comparing clopidogrel with ticagrelor. J Neuroradiol 46(6):378\u2013383","journal-title":"J Neuroradiol"},{"issue":"16","key":"3401_CR14","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/eurheartj\/ehv491","volume":"37","author":"E Hagstrom","year":"2016","unstructured":"Hagstrom E, James SK, Bertilsson M, Becker RC, Himmelmann A, Husted S et al (2016) Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J 37(16):1325\u20131333","journal-title":"Eur Heart J"},{"key":"3401_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2016.03.015","volume":"177","author":"YJ Shimada","year":"2016","unstructured":"Shimada YJ, Bansilal S, Wiviott SD, Becker RC, Harrington RA, Himmelmann A et al (2016) Impact of glycoprotein IIb\/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Am Heart J 177:1\u20138","journal-title":"Am Heart J"},{"issue":"2","key":"3401_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/0267659120927857","volume":"36","author":"YR Zhang","year":"2021","unstructured":"Zhang YR, Xue ZK, Chen KY, Xu LX, Wang WD, Tao HY et al (2021) Loading doses of ticagrelor versus clopidogrel in preventing periprocedural myocardial infarction in Asian patients with acute coronary syndrome. Perfusion 36(2):122\u2013129","journal-title":"Perfusion"},{"issue":"1","key":"3401_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3889\/oamjms.2016.018","volume":"4","author":"A Shabaiek","year":"2016","unstructured":"Shabaiek A, Ismael Nel H, Elsheikh S, Amin HA (2016) Role of cardiac myocytes heart fatty acid binding protein depletion (H-FABP) in early myocardial infarction in human heart (autopsy study). Open Access Maced J Med Sci 4(1):17\u201321","journal-title":"Open Access Maced J Med Sci"},{"issue":"11","key":"3401_CR18","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1080\/03007995.2020.1825364","volume":"36","author":"J Li","year":"2020","unstructured":"Li J, Qiu H, Yan L, Guo T, Wang Y, Li Y et al (2020) Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention. Curr Med Res Opin 36(11):1739\u20131745","journal-title":"Curr Med Res Opin"},{"issue":"14","key":"3401_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015990","volume":"9","author":"S Volz","year":"2020","unstructured":"Volz S, Petursson P, Odenstedt J, Ioanes D, Haraldsson I, Angeras O et al (2020) Ticagrelor is not superior to clopidogrel in patients with acute coronary syndromes undergoing PCI: a report from Swedish Coronary Angiography and Angioplasty Registry. J Am Heart Assoc 9(14):e015990","journal-title":"J Am Heart Assoc"},{"key":"3401_CR20","volume":"27","author":"J Alfredsson","year":"2020","unstructured":"Alfredsson J, Omar K, Csog J, Venetsanos D, Janzon M, Ekstedt M (2020) Bleeding complications with clopidogrel or ticagrelor in ST-elevation myocardial infarction patients - a real life cohort study of two treatment strategies. Int J Cardiol Heart Vasc 27:100495","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"5","key":"3401_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232768","volume":"15","author":"T Charpentier","year":"2020","unstructured":"Charpentier T, Ferdynus C, Lair T, Cordier C, Brulliard C, Valance D et al (2020) Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: a propensity-score matching analysis. PLoS ONE 15(5):e0232768","journal-title":"PLoS ONE"},{"issue":"7","key":"3401_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41569-020-0393-9","volume":"17","author":"K Huynh","year":"2020","unstructured":"Huynh K (2020) Clopidogrel is a favourable alternative to ticagrelor in older patients with NSTE-ACS. Nat Rev Cardiol 17(7):384","journal-title":"Nat Rev Cardiol"},{"key":"3401_CR23","doi-asserted-by":"crossref","unstructured":"Gimbel ME, Tavenier AH, Bor W, Hermanides RS, de Vrey E, Heestermans T et al (2020) Ticagrelor versus clopidogrel in older patients with NSTE-ACS using oral anticoagulation: a sub-analysis of the POPular Age Trial. J Clin Med 9(10)","DOI":"10.3390\/jcm9103249"},{"issue":"16","key":"3401_CR24","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","volume":"381","author":"S Schupke","year":"2019","unstructured":"Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J et al (2019) Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 381(16):1524\u20131534","journal-title":"N Engl J Med"},{"issue":"9","key":"3401_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40266-022-00971-w","volume":"39","author":"S Xu","year":"2022","unstructured":"Xu S, Liang Y, Chen Y, Gao H, Tan Z, Wang Q et al (2022) Comparative effectiveness and safety of ticagrelor versus clopidogrel for elderly Chinese Patients undergoing percutaneous coronary intervention: a single-center retrospective cohort study. Drugs Aging 39(9):695\u2013703","journal-title":"Drugs Aging"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03401-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03401-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03401-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T06:03:25Z","timestamp":1668060205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03401-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3401"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03401-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]},"assertion":[{"value":"28 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the First Affiliated Hospital of Soochow University, and all patients provided written informed consent before participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients volunteered to participate in this study and provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}